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Empyema is a severe complication of different diseases and traumas. Management of this
complication  is difﬁcult and should comprise general and local procedures. The general
procedure  is mainly based on administering wide-spectrum antibiotics. Local management
depends  on patient general condition, but in all cases the essential procedure is to insert a
drain into the pleural cavity and to evacuate the pus. Sometimes pus is very thick and its
evacuation  and following re-expansion of the lung is rather impossible. In these patients
surgical  intervention is needed. The use of intrapleural enzymes to support the drainage
was  ﬁrst described in 1949 by Tillett and Sherry using a mixture of streptokinase and strep-
tococcal  deoxyribonuclease. Nowadays, puriﬁed streptokinase has come into widespread
use,  but recent studies reported no streptokinase effect on pus viscosity. On the other side,
deoxyribonuclease  reduces pus viscosity and may be more useful in treatment. We  reporttwo  cases of intrapleural administration of Pulmozyme (alfa dornase – deoxyribonuclease
(HOFFMANN-LA ROCHE AG) in dosage 2 × 2.5 mg with a signiﬁcant improvement caused by
changes  in pus viscosity.
© 2013 Elsevier Editora Ltda.      Este é um artigo Open Access sob a licença de CC BY-NC-NDIn this study we describe case reports of two patients with
pleural  empyema  treated by intrapleural administration of
deoxyribonuclease (DNase).
Patient  no.  1A 33-year-old male was  admitted to the Pneumonology
Department because of chest pain on the right side, high
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Este é um artigo Open Access sob a licença temperature (±39 ◦C) and weight loss of about 5 kg which
has  been observed within 3 weeks. Clinical examination
and chest X-ray revealed a pleural empyema. Laboratory
examination of the peripheral blood was  done. (There
were 20.9 K/L leucocytes, 4.32 K/L erythrocytes, 12.4 g/dL
haemoglobin, 1.1 mol/L creatinine, 357.1 mg/L CRP protein, Prague, Department of Tumor Biology, Ruska 87, 100 97 Prague,
thrombocytes 406 K/L, 4.6 mmol/L kalium, LDH  694 U/L,
albumin  2.6 g/dL, GOT/AspAT 43 U/L, and GPT/ALAT 42 U/L)
The  patient was  treated with intravenous broad spectrum
de CC BY-NC-ND
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ntibiotics: cefuroxim (Zinacef 3 × 750 mg  iv), amikacin (Bio-
acin  2 × 500 mg  iv), Metronidazol (3 × 500 mg  iv). At the
eginning microbiological cultivation was negative. Later
taphylococcus aureus K (−) metycilin resistant was  detected.
ccording to the sensitivity Lincomycin 600 mg  iv every 8 h
as  introduced. Zinacef and Biodacin were put aside.
Thoracentesis was  performed but no ﬂuid was obtained.
he  patient was  relocated to the Thoracic Surgery Centre,
here  the chest tube was  inserted into the pleural cavity. Drain
as  inserted into the pleural cavityin local analgesia (1% ligno-
ain).  Drain (size 36) was  introduced in the posterior axillary
ine  in the VIII intercostal space and was  connected to the
ucking  system 20 mmH2O. Ultrasonography of pleural cav-
ty  was  done and loculated ﬂuid was  diagnosed. Second drain
as  introduced into the empyema  cavity. Additionally the
uppurative  inﬁltration of the chest wall was  conﬁrmed. The
ncision  of the chest wall was  done and the second drainage
drain  size 28) was  introduced into the suppurative space of
he  chest wall. Drains were connected into the two different
ucking  systems. The position of both drains was  controlled
y  X-ray. The effect of treatment was  not satisfactory. During
he  ﬁrst days only a small amount of pus from pleural cav-
ty  was  removed because of high pus density. Within the ﬁrst
ay  the amount of pleural ﬂuid was  300 mL,  within the sec-
nd  only 30 mL,  and on the third 20 mL.  In the subsequent
wo days Pulmozyme was  administered directly into the pleu-
al  cavity through the drain. The total amount of Pulmozyme
dministered was  5 mg.  2.5 mg of dornase alfa and 50 mL  of
ormal  saline were instilled into the pleural cavity daily for
 consecutive days. The tube was  clamped for 4 h after instil-
ation  of this agent. During this period patient changed the
osition  (lateral, supine, face down  position). On the day 1
fter  Pulmozyme application 900 mL  of thin pus was  drained;
n  the day 2, a further 300 mL of drainage was  collected with
ig. 1 – Patient no. 1. (A) Chest X-ray performed before treatment
-ray performed after introducing two doses of Pulmozyme. (D) C 1 3;1  7(1):90–93  91
considerable  improvement in the X-ray and the patient’s clin-
ical  status. His appetite improved and temperature decreased.
The  chest drain was  removed on day 10.
Patient  No.  2
A 21-year-old male was admitted with a 4 weeks history
of  fevers and rigours with breathlessness. The patient was
treated  in out-patient regime by antibiotics (erythromycin)
without microbiological investigation or antibiotic sensitiv-
ity  testing. Thoracentesis was  performed with evacuation of
100  mL of pus. The patient was  relocated to the Thoracic
Surgery Centre, where the chest tube was inserted into the
pleural  cavity. Drain was inserted into the pleural cavity in
local  analgesia (1% lignocain). Drain (size 32) was introduced in
the posterior axillary line in the VIII intercostal space and was
connected  to the sucking system 20 mmH2O. Control ultra-
sonography and X-ray of pleural cavity were  performed. The
patient  was  treated with intravenous broad spectrum antibi-
otics:  cefuroxim (Zinacef 3 × 750 mg  iv) amikacin (Biodacin
2  × 500 mg  iv), Metronidazol (3 × 500 mg  iv). The Streptococ-
cus pneumoniae was  detected and examined as sensitive for
applied  antibiotics mentioned above.
Clinical examination and chest X-ray revealed a pleu-
ral  empyema. Laboratory examination of the sample of the
peripheral  blood was done. (There were 16.7 K/L leuco-
cytes, 4.2 K/L erythrocytes, 16.7 g/dL haemoglobin, 254 mg/L
CRP  protein, thrombocytes 412 K/L, bilirubin total 0.5 mg/dL,
kalium  4.1 mmol/L, LDH 594 U/L, albumin 2.9 g/dL, GOT/AspAT
47  U/L, and GPT/ALAT 45 U/L.)
During  the ﬁrst days only a small amount of pus from pleu-
ral  cavity was  removed because of high pus density. On  day
1  the amount of pleural ﬂuid was 220 mL,  day 2 only 80 mL,
. (B) Chest X-ray performed after inserting drain. (C) Chest
hest X-ray performed after removing drain.
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Fig. 2 – Patient no. 2. (A) Chest X-ray performed before treatment. (B) Chest X-ray performed after inserting drain. (C) Chest
. (D) CX-ray performed after introducing two doses of Pulmozyme
and day 3 – 40 mL.  In the subsequent two days Pulmozyme
was  administered directly into the pleural cavity through the
drain.  The total amount of the administered Pulmozyme was
5  mg.  2.5 mg  of dornase alfa and 50 mL  of normal saline were
instilled  into the pleural cavity daily for 2 consecutive days.
The  tube was  clamped for 4 h after instillation of this agent.
On  ﬁrst day after Pulmozyme application 700 mL  of thin pus
was  drained; on second day a further 400 mL  of drainage was
obtained  with considerable improvement in the X-ray and the
patient’s  clinical status. His appetite improved and tempera-
ture  decreased. The chest drain was  removed on day 12.
In  both patients the ﬁrst chest X-ray (Figs. 1A and 2A) was
performed before treatment and the last one (Figs. 1D and 2D)
after removing the drain. After release from the hospital the
patient  was  controlled in the hospital outpatient clinic. The
X-ray  done after 1 month was  better than the ones shown in
Fig.  2.
Measurement  of  viscosity
To measure drainability a 2 mL  medical syringe ﬁtted with
1.2  × 40 (18G × 11/2 ′′) needle was  used.Patient  no.  1
The measurement of viscosity before instillation of the dor-
nase  alfa was  56 drops/min. After instillation of the ﬁrsthest X-ray performed after removing drain.
dornase  alfa dose it was  210 drops/min and after the second
dose  225 drops/min.
Patient  no.  2
The viscosity before instillation of dornase alfa was
10  drops/min and after instillation of dornase alfa
86  drops/min.
Discussion
Successful treatment of pleural empyema  depends on ade-
quate  drainage of pleural cavity. There are other factors which
prevent  successful drainage by intercostals tube: chest tube
size,  loculation of the ﬂuid and increasing viscosity, and
adherence of the pus to the pleural surfaces, possibly pre-
venting  lung re-expansion by coating the visceral pleura.
There  are many  studies which suggest to use intra-pleural
ﬁbrinolytic therapy especially streptokinase and urokinase in
treatment of multiloculated pleural empyemas with good suc-
cess rate. Some authors suggest that intrapleural instillation
of  ﬁbrinolytic agents appears to be an effective and less inva-
sive  alternative to surgical treatment.3–6 The results of some
7,8control  studies using puriﬁed streptokinase are divergent.
Simpson et al. suggest that puriﬁed streptokinase was less
effective  than the older drug preparation which has contained
a  small proportion of streptococcal DNase.2,9
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In the randomized, multicentre trial (MIST-1) the posi-
ive  effect of streptokinase in pleural infections could not be
ubstantiated.10
Although streptokinase lyses adhesions, it does not reduce
us  viscosity.2 It is possible that combination of agents that
educe  pus viscosity and break down loculations may  be more
ffective  in the infected pleural space drainage. Recently, an
ntrapleural  DNase-administration could be used in combi-
ation  with thrombolytic therapy to enhance pus drainage.
n  an animal model, the combination of recombinant tissue
lasminogen activator (alteplase) and recombinant human
eoxyribonnuclease (rhDNase) has been shown to be more
ffective  in treating empyema  than either agent used
lone.11
Intrapleural use of a ﬁbrinolytic agent (to disrupt adhe-
ions) and DNase (to decrease pus viscosity) may  promote
fﬁcient drainage of pus in empyema. This should be con-
rmed  by the recently completed Multi-centre Intrapleural
epsis Trial (MIST-2 To date, this is the largest, multi-
entre, randomized, controlled trial, in which patients
ere  randomized in a 1:1 fashion into 4 treatment arms.
he  four treatment groups included: (1) ﬁbrinolytics plus
Nase;  (2) ﬁbrinolytics alone; (3) DNase alone; and (4)
aline.
Combination of intrapleural tPA/DNase was  signiﬁcantly
uperior to the other combinations in improving pleural ﬂuid
rainage.  DNase or tPA alone are ineffective. The proportion
f  patients dying or requiring surgery for their infection was
igher  in the DNase and saline group.
Pulmozyme is a recombinant DNAse that digests DNA
n  the mucous secretions in lungs. Alteplase and Reteplase
re  the second generation recombinant tPAs. Pulmozyme
leaves extracellular DNA in mucus of cystic ﬁbrosis
atients, reducing the adhesiveness and viscoelasticity of the
ucus.
Human  recombinant DNase seems to be extremely safe
nd  effective when it is administered by nebulization in the
reatment  of cystic ﬁbrosis.1 Similarly, treating empyema  by
Nase  could be promising for patients in future.
onclusionulmozyme may  be used in some patients with pleural
mpyema  with good results.
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